Wide Ranks

EYPT

EyePoint Pharmaceuticals, Inc.

9.05

Top Statistics
Market Cap 617 M Forward PE -3.57 Revenue Growth -30.80 %
Current Ratio 5.50 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -226.57 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -3.38 Enterprise / Revenue 8.47 Price To Sales Trailing12 Months 13.51
Profitability
Profit Margins -226.57 % Operating Margins -311.17 %
Balance Sheet
Total Cash 253 M Total Cash Per Share 3.72 Total Debt 23 M
Total Debt To Equity 10.56 Current Ratio 5.50 Book Value Per Share 4.09
All Measures
Short Ratio 953.00 % Message Board Id finmb_4481199 Fax 617 926 5050
Shares Short Prior Month 9 M Return On Equity -0.7468 City Watertown
Uuid 564ca7d9-104b-3085-b6a2-17354e99fc88 Previous Close 9.00 First Trade Date Epoch Utc 1 B
Book Value 4.09 Beta 1.52 Total Debt 23 M
Volume 532373 Price To Book 2.21 Last Split Date 1 B
Fifty Two Week Low 5.98 Total Cash Per Share 3.72 Total Revenue 45 M
Shares Short Previous Month Date 1 B Target Median Price 30.00 Max Age 86400
Recommendation Mean 1.33 Sand P52 Week Change 0.3133 Operating Margins -311.17 %
Target Mean Price 33.45 Net Income To Common -103570000 Short Percent Of Float 0.1636
Implied Shares Outstanding 68 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Total Cash 253 M
Next Fiscal Year End 1 B Revenue Per Share 0.9020 Held Percent Insiders 0.0114
Ebitda Margins -250.66 % Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 9.00 Target Low Price 18.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 9.78 Open 9.12
Free Cashflow -59128500 State MA Dividend Yield 0.00 %
Return On Assets -0.3139 Time Zone Short Name EST Trailing Eps -1.99
Day Low 8.95 Address1 480 Pleasant Street Shares Outstanding 68 M
Price Hint 2 Target High Price 68.00 Website https://eyepointpharma.com
52 Week Change 0.4480 Average Volume 818001 Forward Eps -2.83
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 520.90 %
Last Split Factor 1:10 Regular Market Day High 9.22 Is_sp_500 False
Profit Margins -226.57 % Debt To Equity 10.56 Fifty Two Week High 30.99
Day High 9.22 Shares Short 9 M Regular Market Open 9.12
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 8.47
Revenue Growth -30.80 % Shares Percent Shares Out 0.1447 Operating Cashflow -113486000
Currency USD Time Zone Full Name America/New_York Market Cap 617 M
Is_nasdaq_100 False Zip 02472 Quote Type EQUITY
Industry Biotechnology Long Name EyePoint Pharmaceuticals, Inc. Regular Market Day Low 8.95
Held Percent Institutions 0.9343 Current Price 9.05 Address2 Suite A-210
Enterprise To Ebitda -3.38 Financial Currency USD Current Ratio 5.50
Gross Margins -141.06 % Industry Disp Biotechnology Number Of Analyst Opinions 11
Country United States Float Shares 47 M Two Hundred Day Average 13.15
Enterprise Value 386 M Price To Sales Trailing12 Months 13.51 Forward PE -3.57
Regular Market Volume 532373 Ebitda -114583800 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.

The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).

The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases.

The company was formerly known as pSivida Corp.

and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.

EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.